HOOKIPA Pharma (HOOK) said Thursday it struck a deal to sell its key assets from its HB-400 program for hepatitis B virus and HB-500 program for human immunodeficiency virus program to Gilead Sciences (GILD) for up to $10 million.
These programs are currently in clinical development, the company said in a regulatory filing. Gilead will not acquire other assets, including its HB-500 phase 1b clinical trial.
HOOKIPA said it will receive $3 million upfront at closing, with up to $7 million due in three phases.
Shares of HOOKIPA rose past 11% in recent trading.
Price: 1.72, Change: +0.20, Percent Change: +13.16
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.